Cervarix TM

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, Papillomavirus

Phase 1

Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)

CompletedNCT00478621

GlaxoSmithKlineInfections, Papillomavirus

Start: 2007-05-25End: 2008-10-13Updated: 2017-05-10

Phase 3

Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years

CompletedNCT00456807

GlaxoSmithKlineInfections, Papillomavirus

Start: 2007-04-30End: 2008-01-31Updated: 2016-12-16

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

CompletedNCT00552279

GlaxoSmithKlineInfections, Papillomavirus

Start: 2007-11-12End: 2009-07-20Updated: 2018-06-25

Related Papers

Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.

2014-03-2517 citations

Results disclosure of papilloma vaccine studies in humans completed before January 1st, 2011.

Figshare2014-01-01

Results disclosure of papilloma vaccine studies in humans co.

Figshare2014-01-01

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study.

2011-03-0126 citations